Here's the most comprehensive list of VR1 players I've seen to date, from a recent filing by Anesiva:
"VR1 inhibitors that may also compete with 4975 are being developed by several companies, including Merck-Neurogen, Pfizer-Renovis, Amgen, Schwarz Pharma-Amore Pacific, Purdue Pharma, and PainCeptor. These VR1 inhibitors are expected to advance to clinical evaluation shortly."
This is from mid-2006. Even then, NRGN's version was already being clinically evaluated, and GSK's, not mentioned above, may now also be in humans.
Cheers, Tuck |
